Prognostic and Predictive Significance of Microsatellite Status in Patients with Colorectal Cancer in Stage II and Stage III Disease: Single-Centre Experience
Abstract
Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related morbidity and mortality worldwide. Microsatellite instability (MSI) is a crucial biomarker with prognostic and predictive value, influencing treatment decisions in CRC.
Methods: This retrospective study investigated the impact of the MSI status on clinical outcomes in 184 CRC patients treated at the Oncology Institute of Vojvodina between 2018 and 2023. The MSI status was determined using the immunohistochemical analysis of mismatch repair proteins.
Results: Among the cohort, 75% of tumors were microsatellite-stable (MSS), 4.3% exhibited low MSI (MSI-L), and 20.6% displayed high MSI (MSI-H). MSI-H tumors were significantly associated with right-sided CRC, mucinous differentiation, and female gender (p<0.05). The survival analyses revealed that the MSI-H patients with stage II disease had significantly better disease-free survival (DFS) and overall survival (OS) than the MSS counterparts (p=0.024 and p=0.006, respectively). Conversely, the MSI-H status in stage II patients receiving adjuvant therapy was linked to shorter DFS (p=0.000), highlighting the limited benefit from 5-fluorouracil-based regimens. In stage III CRC, the MSI status did not significantly affect DFS or OS.
Conclusion: These findings underscore the dual role of MSI as a favorable prognostic marker in early-stage CRC and a predictor of the reduced benefit from adjuvant chemotherapy in stage II disease. This study emphasizes the need for individualized treatment strategies based on the MSI status and supports the potential integration of immunotherapy in the adjuvant setting for MSI-H CRC.
References
Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCANGut 2023;72:338-44.
International Agency for Research on Cancer. GLOBOCAN 2021: Serbia Fact Sheet [Internet]. Global Cancer Observatory; 2021 [cited 2024 Dec 5]. Available from: https://gco.iarc.who.int/
Zhao J, Xu L Sunet J al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019.BMJ Oncology 2023;2:e000049.
Battaglin F, Naseem M, Lenz H, Salem M. Microsatellite instability in Colorectal Cancer: Overview of its Clinical significance an Novel Perspectives.Clin Adv Hematol Oncol.2018 November;16 (11):735-45
Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863-75.
Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(2):e240029.
Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T et al. ESMO Guidelines Committee.Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-05.
Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16(7):30.
Puccini, A.; Berger, M.D.; Zhang, W.; Lenz, H.J. What We Know About Stage II and III Colon Cancer: It’s Still Not Enough. Target Oncol. 2017;12(3):265–75.
Kim SE, Paik HY, Yoon H, Lee JE, Kim N, Sung MK. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015;21(17):5167-75.
Choi Y, Kim N. Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis. World J Mens Health. 2024;42(2):256-82.
Acar T, Acar N, Kamer E, Cengiz F, Tekindal MA, Bağ H et al. Do tumor localization, microsatellite instability and mismatch repair deficiency have an impact on the prognosis of colorectal cancer? Niger J Clin Pract. 2021;24(12):1814-23.
Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg. 2021;13(12):1567-83.
Taieb J, Karoui M, Basile D. How I treat stage II colon cancer patients. ESMO Open. 2021;6(4):100184.
Shaib WL, Zakka KM, Jiang R, Yan M, Alese OB, Akce M et al. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. Cancer. 2020;126(18):4136-47.
Tomasello G, Ghidini M, Galassi B, Grossi F, Luciani A, Petrelli F. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis. Sci Rep. 2022;12(1):1055.
Koenig JL, Toesca DAS, Harris JP, Tsai CJ, Haraldsdottir S, Lin AY, et al. Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. Am J Clin Oncol. 2019;42(7):573-80.
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45(10):1890-6.
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C et al. KEYNOTE-177 Investigators. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659-70.
